Replies to post #41075 on Ariad Pharmaceuticals Inc fka ARIA

[ChicagoGolfer12]

Good points.

[Euripides90]

Yes the company sure isn't helping with their lack of updates, still the old news announcing presentations now passed. Maybe they don't want to give appearance of influencing the market but they need to say something, I HOPE they're working on it.

There are conflicting forces at play, the upgrade to BUY from Stifel and target of $7.00 but "upgrade" by Jefferies to 4.00 may have set another goal, absent additional boosts.

Hope you're wrong about continued "plummet" and I feel compelled to offer balance here, to discourage further mass fear: IMO this (4.20-ish) is at or near bottom, however no doubt our previous poster isn't alone trying to short it down to 3's and I have been duly corrected that hedge funds which own the large majority do not short either...statistics and ample evidence to the contrary.

So there is a concerted effort to take it down BUT the long-term prognosis is good. However if even the optimistic analyst at Stifel could only project the FDA allowing Iclusig back on the market with EMA-type restrictions by sometime 2ndQ 2014, what's the hurry in snapping up shares now some might figure?
Wny not drive down the price as much as possible to load in anticipation of news?

This opinion may be carrying the day: that while the long-term prognosis is good and the FDA is expected to allow the drug to return to market, "there is a clear unmet need," but "in time."

That would put the price above $4.00-4.14 as a floor/bottom support, but there doesn't seem to be a hurry to reach the $7.00 target.

Price: $4.24 -4.5%

Summer Street maintained an Neutral rating on ARIAD Pharmaceuticals (NASDAQ: ARIA).

A consultant with the firm said there was no new information from the PACE data at ASH. For analyst Carol Werther, that can be taken positively or negatively.

"ARIA appears to have the support of its clinicians regarding the drug's safety. The larger challenge will be the label changes and REMS program as they work with the FDA. We believe the drug provides a clear unmet need and will return in time," said Summer Street.

She could've just as well said "buy" for long-term but she didn't.

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $4.29 yesterday, with a 52 week range of $2.15-$24.59.

(update: adding the link:)

http://www.streetinsider.com/Analyst+Comments/ARIAD+Pharma+%28ARIA%29%3A+No+New+Information+From+PACE+Data+at+ASH+-+Summer+Street/8963679.html